City of Huntington, West Virginia v. AmerisourceBergen Drug Corporation

District Court, S.D. West Virginia·Decided March 15, 2021·No. 3:17-cv-01362·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF WEST VIRGINIA THE CITY OF HUNTINGTON, Plaintiff, v. CIVIL ACTION NO. 3:17-01362 AMERISOURCEBERGEN DRUG CORPORATION, et al., Defendants. ________________________________ CABELL COUNTY COMMISSION, Plaintiff, v. CIVIL ACTION NO. 3:17-01665 AMERISOURCEBERGEN DRUG CORPORATION, et al., Defendants. ________________________________ MEMORANDUM OPINION AND ORDER Pending before the court is plaintiffs’ motion for partial summary judgment regarding ARCOS data. See ECF No. 1008. That motion is fully briefed and was argued before the court on January 6, 2021. I. The Controlled Substances Act of 1970 requires manufacturers and distributors to report their controlled substances transactions to the Drug Enforcement Administration (DEA). See https://www.deadiversion.usdoj.gov/arcos. (last visited March 8, 2021). The DEA maintains the Automation of Reports and Consolidated Orders System (“ARCOS”), an “automated, comprehensive drug reporting system which monitors the flow of DEA controlled substances from their point of manufacture through commercial distribution channels to point of sale or distribution at the dispensing/retail level - hospitals, retail pharmacies, practitioners, mid-level practitioners, and teaching institutions.” Id. “ARCOS accumulates these transactions which are then summarized into reports which give investigators in Federal and state government agencies information which can then be used to identify the diversion of controlled substances into illicit channels of distribution.” Id. The ARCOS database “includes supplier name, registration number, address and business activity; buyer name, registration number and address; as well as

drug code, transaction date, total dosage units, and total grams.” In re Nat. Prescription Opiate Litig., 927 F.3d 919, 924 (6th Cir. 2019). In the MDL, the DEA produced a set of ARCOS Data reflecting transactions of drug products containing one or more of fourteen opioid drugs during the time period January 1, 2006 through December 31, 2014. See ECF No. 1008-2 at 2 (Excerpts of Expert Report of Dr. Craig J. McCann). The DEA produced this data in stages and Dr. McCann summarized the production in his expert 2 report. See id. at 2-3. Dr. McCann reported that the ARCOS Data contained 500,709,803 total transaction records. See id. In the MDL, defendants, including Cardinal Health, stipulated to the accuracy of the ARCOS Data as produced by the DEA. See ECF No. 2675 in Case No. 1:17-md-02804 at 2 (“The documents produced by the United States Drug Enforcement Administration (“DEA”) related to Automated Records and Consolidated Orders System (“ARCOS Data”) reflecting transactions in drug products containing one or more of fourteen drugs: buprenorphine, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, powdered opium, oxycodone, oxymorphone, and tapentadol for the period of January 1, 2006 through December 31, 2014 shall be deemed authentic and presumed admissible for the purposes of this litigation.”). Dr. McCann adjusted the raw ARCOS data in several ways, in

some cases removing certain transactions. See ECF No. 1008-2 at 5-6. He also compared the ARCOS data to Retail Drug Summary Reports produced by the DEA1 to confirm the accuracy of the ARCOS data received. See id. at 6-7. Dr. McCann also reviewed transaction data produced in discovery by defendants and found 1 The DEA publishes six ARCOS Retail Drug Summary Reports each year that summarize the weight of opioids reported in ARCOS transactions. See ECF No. 1008-2 at 6; see also ECF No. 2675 in Case No. 1:17-md-02804 at 2 (“DEA can and does use ARCOS data to create summary reports showing how many controlled substances were manufactured and distributed throughout the United States.”). 3 small gaps in the data produced. See id. at 8. Ultimately, Dr. McCann concluded that the overlap between the ARCOS data and the transactional data from defendants demonstrated that both sets of data are reliable. See id. at 9. Plaintiffs, pursuant to Rule 56 of the Federal Rules of Civil Procedure, seek an order granting partial summary judgment and holding that the ARCOS data received by the DEA and processed by Dr. McCann accurately reflects the shipments of opioid products reported to the DEA by DEA licensed wholesale distributors (“Processed ARCOS Data”). According to plaintiffs, because there is no factual dispute that Dr. McCann’s Processed ARCOS Data accurately reflects the data provided by the DEA regarding the defendants’ shipments of opioids, this court should grant partial summary judgment on this question.

Free access — add to your briefcase to read the full text and ask questions with AI

City of Huntington, West Virginia v. AmerisourceBergen Drug Corporation, (S.D.W. Va. 2021).

City of Huntington, West Virginia v. AmerisourceBergen Drug Corporation (City of Huntington, West Virginia v. AmerisourceBergen Drug Corporation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related